Solid Biosciences (SLDB) vs Surrozen (SRZN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Surrozen (SRZN) has outperformed Solid Biosciences (SLDB) over the past year, gaining 115.6% versus a gain of 33.0%. Over five years, SLDB leads with a -77.8% price change compared with -79.0% for SRZN. Solid Biosciences is the larger company by market cap ($697.6 million vs $596.4 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SLDB | SRZN |
|---|---|---|
| Share price | $6.25 | $28.46 |
| Market cap | $697.57M | $596.40M |
| 1-day change | -2.95% | -7.21% |
| YTD return | +10.82% | +25.93% |
| 1-year return | +32.98% | +115.61% |
| 5-year return | -77.78% | -78.97% |
| EPS (TTM) | $-1.76 | $-41.94 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $3.48M |
| Revenue growth (YoY) | — | -67.37% |
| Net income (latest FY) | $-174.32M | $-242.03M |
| Operating margin | — | -1210.58% |
| Net margin | — | -6960.77% |
| 52-week high | $11.45 | $37.83 |
| 52-week low | $4.65 | $12.79 |
| Distance from 52-week high | -45.41% | -24.77% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +199.36% | +123.12% |
| Average volume | 1.30M | 537.16K |
| Shares outstanding | 111.61M | 20.96M |
| Employees | 121 | 44 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SRZN has outperformed SLDB by 82.6 percentage points over the past year.
About Solid Biosciences
SLDB stock →Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 121 employees
About Surrozen
SRZN stock →Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees
SLDB vs SRZN FAQ
Which is bigger, Solid Biosciences or Surrozen?
Solid Biosciences (SLDB) is larger, with a market capitalization of $697.57M compared with $596.40M for Surrozen (SRZN).
Which stock has performed better over the past year, SLDB or SRZN?
SRZN returned +115.61% over the past 12 months, compared with +32.98% for SLDB (price return, excluding dividends). Past performance does not predict future results.
Are Solid Biosciences and Surrozen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.